Anacor Pharmaceuticals Company Profile (NASDAQ:ANAC)

About Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals logoAnacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ANAC
  • CUSIP: 03242010
  • Web:
Average Prices:
  • 50 Day Moving Avg: $93.23
  • 200 Day Moving Avg: $81.52
  • 52 Week Range: $52.00 - $156.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -162.62
  • P/E Growth: 0.00
  • Net Margins: -92.08%
  • Return on Equity: -133.71%
  • Return on Assets: -38.09%
  • Average Volume: 2.54 million shs.

Frequently Asked Questions for Anacor Pharmaceuticals (NASDAQ:ANAC)

What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

How were Anacor Pharmaceuticals' earnings last quarter?

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) announced its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.36) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.01. The company had revenue of $17.54 million for the quarter, compared to analyst estimates of $19.53 million. Anacor Pharmaceuticals had a negative net margin of 92.08% and a negative return on equity of 133.71%. The firm's quarterly revenue was up 14.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.30) EPS. View Anacor Pharmaceuticals' Earnings History.

Who are some of Anacor Pharmaceuticals' key competitors?

How do I buy Anacor Pharmaceuticals stock?

Shares of Anacor Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anacor Pharmaceuticals' stock price today?

One share of Anacor Pharmaceuticals stock can currently be purchased for approximately $99.20.

MarketBeat Community Rating for Anacor Pharmaceuticals (NASDAQ ANAC)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  66 (Vote Underperform)
Total Votes:  283
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Anacor Pharmaceuticals (NASDAQ:ANAC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Price Target History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Analysts' Ratings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2016MizuhoDowngradeBuy -> Neutral$98.00 -> $99.25N/AView Rating Details
5/16/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
5/16/2016WedbushDowngradeOutperform -> Neutral$148.00 -> $99.25N/AView Rating Details
5/10/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Earnings by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)
Earnings History by Quarter for Anacor Pharmaceuticals (NASDAQ ANAC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.35)($0.36)$19.53 million$17.54 millionViewListenView Earnings Details
2/29/2016Q415($0.30)($0.43)$27.93 million$21.20 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.37)$25.60 million$24.60 millionViewListenView Earnings Details
8/6/2015Q215($0.32)($0.30)$18.55 million$21.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.47)($0.30)$9.20 million$15.26 millionViewN/AView Earnings Details
3/12/2015Q414($0.59)($0.21)$4.74 million$9.60 millionViewN/AView Earnings Details
11/6/2014Q314($0.65)($0.74)$3.67 million$3.96 millionViewN/AView Earnings Details
8/7/2014Q214($0.63)($0.58)$3.03 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.39)($0.51)$2.82 million$4.15 millionViewN/AView Earnings Details
3/13/2014Q413$3.01$3.01$2.85 million$8.50 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.39)($0.36)$2.60 million$3.40 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.42)$2.57 million$1.71 billionViewN/AView Earnings Details
3/14/2013Q4 2012($0.45)($0.36)$3.25 million$3.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.45)($0.46)$3.18 million$2.47 millionViewN/AView Earnings Details
8/9/2012($0.45)($0.47)ViewN/AView Earnings Details
5/10/2012($0.44)($0.48)ViewN/AView Earnings Details
3/13/2012($0.35)($0.52)ViewN/AView Earnings Details
11/10/2011($0.41)($0.16)ViewN/AView Earnings Details
8/11/2011($0.45)($0.54)ViewN/AView Earnings Details
5/5/2011($0.31)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Anacor Pharmaceuticals (NASDAQ:ANAC)
2017 EPS Consensus Estimate: $2.98
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.53)($0.53)($0.53)
Q2 20171$0.52$0.52$0.52
Q3 20171$1.32$1.32$1.32
Q4 20171$1.67$1.67$1.67
(Data provided by Zacks Investment Research)


Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Anacor Pharmaceuticals (NASDAQ:ANAC)
Insider Trades by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)
Institutional Ownership by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)
Insider Trades by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Graeme BellCFOSell751$99.28$74,559.28View SEC Filing  
5/23/2016Keith R LeonardDirectorSell9,000$99.70$897,300.00View SEC Filing  
5/16/2016Anders D HoveDirectorSell353,881$99.59$35,243,008.79View SEC Filing  
4/29/2016Ryan T SullivanEVPSell3,125$66.33$207,281.25View SEC Filing  
4/8/2016Anders D HoveDirectorSell229,301$71.10$16,303,301.10View SEC Filing  
3/22/2016Paul L BernsCEOSell37,500$60.31$2,261,625.00View SEC Filing  
1/19/2016Vincent P. IppolitoEVPSell20,000$95.41$1,908,200.00View SEC Filing  
1/15/2016Lee ZaneSVPSell1,466$89.57$131,309.62View SEC Filing  
1/4/2016Paul L. BernsCEOSell2,533$112.35$284,582.55View SEC Filing  
1/4/2016Ryan T. SullivanVPSell733$111.78$81,934.74View SEC Filing  
1/4/2016Vincent P. IppolitoEVPSell855$112.28$95,999.40View SEC Filing  
12/11/2015Paul L. BernsCEOSell20,000$117.26$2,345,200.00View SEC Filing  
12/10/2015Ryan T. SullivanVPSell10,000$110.41$1,104,100.00View SEC Filing  
9/15/2015Lee ZaneSVPSell14,000$139.84$1,957,760.00View SEC Filing  
9/15/2015Paul L. BernsCEOSell20,000$139.83$2,796,600.00View SEC Filing  
8/13/2015Paul L BernsCEOSell20,000$138.69$2,773,800.00View SEC Filing  
6/15/2015Lee ZaneSVPSell12,000$69.05$828,600.00View SEC Filing  
5/15/2015Jacob J PlattnerVPSell8,920$63.73$568,471.60View SEC Filing  
5/14/2015Carmen R RodriguezVPSell61,942$62.73$3,885,621.66View SEC Filing  
4/29/2015Ryan T SullivanVPSell3,125$53.61$167,531.25View SEC Filing  
4/27/2015Paul L BernsCEOSell50,000$63.64$3,182,000.00View SEC Filing  
4/15/2015Jacob J PlattnerVPSell8,920$62.81$560,265.20View SEC Filing  
3/23/2015Geoffrey M ParkerCFOBuy3,000$52.43$157,290.00View SEC Filing  
3/16/2015Jacob J PlattnerVPSell8,920$55.60$495,952.00View SEC Filing  
3/16/2015Lee ZaneSVPSell12,000$56.44$677,280.00View SEC Filing  
3/4/2015Sanjay ChandaSVPSell5,000$45.00$225,000.00View SEC Filing  
3/3/2015Vincent P IppolitoEVPSell9,000$43.88$394,920.00View SEC Filing  
3/2/2015Jacob J PlattnerVPSell6,875$44.02$302,637.50View SEC Filing  
3/2/2015Kirk R MaplesSVPSell600$43.95$26,370.00View SEC Filing  
1/2/2015Jacob J PlattnerVPSell6,875$32.09$220,618.75View SEC Filing  
12/26/2014Paul L BernsCEOSell25,000$30.82$770,500.00View SEC Filing  
12/12/2014Lucy ShapiroDirectorSell289,685$35.11$10,170,840.35View SEC Filing  
12/11/2014Lee ZaneSVPSell4,900$36.09$176,841.00View SEC Filing  
12/9/2014Kirk R MaplesSVPSell60,000$36.52$2,191,200.00View SEC Filing  
12/1/2014Jacob J PlattnerVPSell6,875$33.34$229,212.50View SEC Filing  
12/1/2014Kirk R MaplesSVPSell600$33.38$20,028.00View SEC Filing  
11/26/2014Sanjay ChandaSVPSell5,000$35.00$175,000.00View SEC Filing  
11/3/2014Jacob J PlattnerVPSell6,875$29.32$201,575.00View SEC Filing  
10/1/2014Jacob J PlattnerVPSell6,875$24.47$168,231.25View SEC Filing  
9/26/2014Anders D HoveDirectorSell20,000$25.00$500,000.00View SEC Filing  
9/19/2014Anders D HoveDirectorSell740,000$24.87$18,403,800.00View SEC Filing  
9/16/2014Anders D HoveDirectorSell90,000$24.99$2,249,100.00View SEC Filing  
9/10/2014Sanjay ChandaSVPSell10,000$24.25$242,500.00View SEC Filing  
9/8/2014Geoffrey M ParkerCFOBuy6,590$21.82$143,793.80View SEC Filing  
8/27/2014Mark LeschlyDirectorSell13,067$22.50$294,007.50View SEC Filing  
5/20/2014Kirk MaplesSVPSell1,500$14.15$21,225.00View SEC Filing  
4/21/2014Kirk MaplesSVPSell1,500$15.60$23,400.00View SEC Filing  
3/24/2014Geoffrey ParkerCFOBuy5,000$20.11$100,550.00View SEC Filing  
3/21/2014Lucy ShapiroDirectorSell80,000$21.14$1,691,200.00View SEC Filing  
3/20/2014Kirk MaplesSVPSell3,000$22.39$67,170.00View SEC Filing  
3/18/2014Geoffrey ParkerCFOBuy2,410$22.60$54,466.00View SEC Filing  
3/5/2014David PerryCEOSell65,000$20.22$1,314,300.00View SEC Filing  
2/20/2014Kirk MaplesSVPSell3,000$19.33$57,990.00View SEC Filing  
2/5/2014David PerryCEOSell15,000$17.00$255,000.00View SEC Filing  
1/21/2014Kirk MaplesSVPSell3,000$20.27$60,810.00View SEC Filing  
1/9/2014David PerryCEOSell65,000$16.32$1,060,800.00View SEC Filing  
12/9/2013David PerryCEOSell40,328$16.23$654,523.44View SEC Filing  
11/26/2013Geoffrey ParkerCFOBuy10,000$13.40$134,000.00View SEC Filing  
11/25/2013Geoffrey ParkerCFOBuy10,000$12.85$128,500.00View SEC Filing  
8/14/2013Kirk MaplesSVPSell1,052$9.71$10,214.92View SEC Filing  
8/13/2013Geoffrey ParkerCFOBuy50,000$8.34$417,000.00View SEC Filing  
6/19/2013Geoffrey M ParkerCFOBuy23,046$5.20$119,839.20View SEC Filing  
6/18/2013Geoffrey M ParkerCFOBuy20,000$5.22$104,400.00View SEC Filing  
6/14/2013Kirk R MaplesSVPSell5,600$5.39$30,184.00View SEC Filing  
11/26/2012Kirk R MaplesSVPSell3,000$5.22$15,660.00View SEC Filing  
11/1/2012Kirk R MaplesSVPSell3,000$5.81$17,430.00View SEC Filing  
10/5/2012Lucy ShapiroDirectorSell30,000$6.67$200,100.00View SEC Filing  
8/22/2012Geoffrey M ParkerCFOBuy5,000$6.19$30,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Anacor Pharmaceuticals (NASDAQ:ANAC)
Latest Headlines for Anacor Pharmaceuticals (NASDAQ:ANAC)
DateHeadline logoBetter Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool - September 17 at 3:41 PM logoBetter Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool - September 17 at 3:40 PM logoSuneva Medical Expands their Prestigious Board of Directors with the Appointment of Vince Ippolito - August 28 at 3:58 PM logoHere's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now ... - Motley Fool - August 21 at 9:00 PM logoShire chief financial officer joins Boston ag-tech startup - August 21 at 4:00 PM logoPfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff - - July 31 at 3:57 PM logoPharma Giant Pfizer Reports Q2 Earnings Tomorrow Morning - Seeking Alpha - July 31 at 3:57 PM logoThese 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now ... - Motley Fool - July 26 at 4:23 PM logoThe Stock Market Is Very Expensive: 5 Safe Blue Chips to Buy Now - July 24 at 1:15 PM logo3 Dividend Stocks That Are Minting Money -- The Motley Fool - Motley Fool - July 13 at 9:46 PM logoNorth America Will Continue to be the Most Lucrative Market for ... - PR Newswire (press release) - June 27 at 3:37 PM logo3 Stocks to Help You Build Retirement Wealth -- The Motley Fool - Motley Fool - June 25 at 8:43 PM logoTop 3 Emerging Trends Impacting the Global Anti-Inflammatory ... - Business Wire (press release) - June 23 at 9:05 PM logoSpherix Inc. Announces Definitive Terms Reached to Acquire ... - PR Newswire (press release) - June 20 at 4:09 PM logoPfizer unloading space after $14 billion Medivation deal - May 8 at 11:01 AM logoPFIZER REPORTS FIRST-QUARTER 2017 RESULTS - May 2 at 7:52 AM logoBiotech M&A Plunges as Trump Attacks Drug Companies - Investopedia - April 24 at 3:34 PM logoCanada's Cannabis Boom Creating a $30 Billion Investment Opportunity - - April 20 at 3:36 PM logo5 Stocks to Watch as Canada Gets Hooked on Cannabis - PR Newswire (press release) - April 18 at 8:34 AM logo1 Top Stock in Big Pharma -- The Motley Fool - Motley Fool - March 27 at 7:32 AM logo1 Top Stock in Big Pharma - Motley Fool - March 25 at 11:40 AM logoBuy Pfizer: Income Play With Good Growth Coming - March 17 at 3:38 PM logoThese Were the 10 Biggest Pharmaceutical Deals of 2016 - Fortune - February 24 at 3:44 PM logoBetter Buy: Pfizer Inc. vs. Merck & Co. Inc. -- The Motley Fool - Motley Fool - February 21 at 3:48 PM logo4 High-Yield Dividend Stocks You Don't Have to Babysit - Motley Fool - February 16 at 8:27 AM logo5 Things Pfizer's Management Wants You to Know - Motley Fool - February 1 at 3:37 PM logoTop 5 Vendors in the Global Atopic Dermatitis Drugs Market from 2017 to 2021: Technavio - Business Wire (press release) - February 1 at 3:37 PM logoAre Pfizer's Acquisitions Holding Back Its Bottom Line? - 24/7 Wall St. - January 31 at 3:42 PM logo3 Reasons to Buy Pfizer Stock and Never Sell -- The Motley Fool - Motley Fool - January 31 at 2:25 AM logoAll Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter ... - - January 31 at 2:25 AM logoA Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour - Benzinga - January 30 at 3:54 PM logoDrugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees - - January 24 at 8:28 PM



Anacor Pharmaceuticals (ANAC) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.